Patients with coexisting glaucoma or AMD received less care on average than their counterparts without the neurodegenerative condition in a recent study.
The effect was seen in patients using these agents to treat systemic inflammation. More work needs to be done before it could be considered a primary therapy for retinal conditions, however.
Researchers acknowledged that lifestyle changes may have also contributed, but nevertheless speculated that the drug may reduce oxidative stress and subsequent VEGF overexpression.